Upstream Bio Inc
For the period ended Dec 31, 2024. Filed Mar 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of attorney (included on signature page)
SIGNA TURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| UPSTREAM BIO, INC. | ||
| Date: March 12, 2025 | By: | /s/ E. Rand Sutherland |
|---|---|---|
| Name: E. Rand Sutherland, M.D. | ||
| Title: Chief Executive Officer | ||
POWER OF ATTORNEY
Each individual whose signature appears below hereby constitutes and appoints each of E. Rand Sutherland, M.D. and Michael Paul Gray, M.B.A. as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons in the capacities and on the date indicated.
| Name | Title | Date |
|---|---|---|
| /s/ E. Rand SutherlandE. Rand Sutherland, M.D. | Chief Executive Officer and Director(Principal Executive Officer) | March 12, 2025 |
| /s/ Michael Paul GrayMichael Paul Gray, M.B.A. | Chief Financial and Operating Officer(Principal Financial Officer andPrincipal Accounting Officer) | March 12, 2025 |
| /s/ Ronald C. Renaud, Jr. Ronald C. Renaud, Jr., M.B.A. | Director and Chairman | March 12, 2025 |
| /s/ Daniella BeckmanDaniella Beckman | Director | March 12, 2025 |
| /s/ Erez ChimovitsErez Chimovits, M.B.A., M.Sc. | Director | March 12, 2025 |
| /s/ H. Edward Fleming, Jr.H. Edward Fleming, Jr., M.D. | Director | March 12, 2025 |
| /s/ Liam RatcliffeLiam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A. | Director | March 12, 2025 |
| /s/ Marcella Kuhlman RuddyMarcella Kuhlman Ruddy, M.D., M.S. | Director | March 12, 2025 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years ended December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Years ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Cash Flows for the Years ended December 31, 2024 and 2023 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.